The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 13, 2021

Filed:

Oct. 11, 2018
Applicant:

Altus Formulation Inc., Mirabel, CA;

Inventors:

Marc Lemieux, Mascouche, CA;

Bradut Mitrasca, Laval, CA;

Sonia Gervais, Laval, CA;

Damon Smith, Ville Saint Laurent, CA;

Assignee:

Altus Formulation Inc., Mirabel, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/38 (2006.01); A61K 31/167 (2006.01); A61K 31/496 (2006.01); A61K 31/138 (2006.01); A61K 31/415 (2006.01); A61K 9/24 (2006.01);
U.S. Cl.
CPC ...
A61K 47/38 (2013.01); A61K 31/138 (2013.01); A61K 31/167 (2013.01); A61K 31/415 (2013.01); A61K 31/496 (2013.01); A61K 9/209 (2013.01);
Abstract

There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function. The release modifying excipient blends overcome problems associated with use of Contramid, and provide a flexible platform for formulation of active pharmaceutical ingredients for controlled release applications.


Find Patent Forward Citations

Loading…